Many retrospective clinical studies have found that the expression of PD-L1 is significantly higher in patients with primary resistance to EGFR–TKIs, and high PD-L1 expression is correlated with shorter PFS in EGFR-mutant NSCLC [30, 46]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.